• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Lupin launches generic Tobramycin Inhalation Solution USP in US

financialexpressJune 14, 2018

Tag: lupin , generic Tobramycin , USP

Lupin has launched Tobramycin Inhalation Solution USP in the US market. The solution has received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin’s Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic equivalent of Novartis Pharmaceuticals Corporation’s Tobi 300 mg/5 ml. It is indicated for the management of cystic fibrosis patients with P. aeruginosa.

Tobramycin Inhalation Solution USP, 300 mg/5 ml had annual sales of approximately USD 99 million in the US (IQVIA MAT April 2018).

Register as Visitor to CPhI China 2018!

Previous:Regenerative bandage accelerates healing in diabetic wounds

Next:Bayer to acquire stake in Monsanto India

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Lupin launches generic Tobramycin Inhalation Solution USP in US | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Glycine usp/Bp

Glycine usp/Bp
L-Glutamic acid AJI/USP Amino acid Food Additive made in china

L-Glutamic acid AJI/USP Amino acid Food Additive made in china
Amoxcillin 15% and Gentamicin sulphate 4% injectable suspension

Amoxcillin 15% and Gentamicin sulphate 4% injectable suspension
Eprinomectin USP

Eprinomectin USP
Cefaclor Synthetic USP37 China

Cefaclor Synthetic USP37 China
Trimebutine maleate for suspension

Trimebutine maleate for suspension
Gemcitabine hydrochloride 98.0%min USP34 Pharmaceutical Anti cancer drugs China

Gemcitabine hydrochloride 98.0%min USP34 Pharmaceutical Anti cancer drugs China
Exemestane 99% USP

Exemestane 99% USP
Sodium Diacetate E262 Preservatives Sodium Diacetate USP Crystal Powder

Sodium Diacetate E262 Preservatives Sodium Diacetate USP Crystal Powder
USP Azithromycin Powder GMP Raw Material Azithromycin

USP Azithromycin Powder GMP Raw Material Azithromycin

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service